TGF-β/Smad signaling in renal fibrosis.
Meng XM, Tang PM, Li J, Lan HY. · 2015
Read TGF-β/Smad signaling in renal fibrosis. by Meng XM, Tang PM, Li J, Lan HY. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4365692.txt.
Introduction
Xiao-Ming Meng, Patrick Tang, Jun Li, and Hui Yao Lan reviewed a signaling path that drives kidney scarring, in Frontiers in Physiology in 2015. The signal protein TGF-beta sits at the center of renal fibrosis, the scarring that advances chronic kidney disease. Inside cells, its messages pass mainly through Smad proteins. The review explains how the balance among those Smads tips toward scarring, and where treatment might push back.
One family member, Smad3, becomes highly active in scarring and helps shut down Smad7, a natural brake, while Smad2 works in the opposite, protective direction. With the brake off, scar-forming cells build up and lay down excess matrix. Small RNAs add another layer of control on Smad3. Raising Smad7 or adjusting those small RNAs eased scarring in mouse models, marking this path as a focused target for kidney therapy.
Catalog record
| CREATOR | Meng XM, Tang PM, Li J, Lan HY. |
|---|---|
| YEAR | 2015 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
TGF-β/Smad signaling in renal fibrosis By Xiao-Ming Meng, Patrick Ming-Kuen Tang, Jun Li, Hui Yao Lan Published in: Frontiers in Physiology DOI: 10.3389/fphys.2015.00082 ABSTRACT TGF-β (transforming growth factor-β) is well identified as a central mediator in renal fibrosis. TGF-β initiates canonical and non-canonical pathways to exert multiple biological effects. Among them, Smad signaling is recognized as a major pathway of TGF-β signaling in progressive renal fibrosis. During fibrogenesis, Smad3 is highly activated, which is associated with the down-regulation of an inhibitory Smad7 via an ubiquitin E3-ligases-dependent degradation mechanism. The equilibrium shift between Smad3 and Smad7 leads to accumulation and activation of myofibroblasts, overproduction of ECM (extracellular matrix), and reduction in ECM degradation in the diseased kidney. Therefore, overexpression of Smad7 has been shown to be a therapeutic agent for renal fibrosis in various models of kidney diseases. In contrast, another downstream effecter of TGF-β/Smad signaling pathway, Smad2, exerts its renal protective role by counter-regulating the Smad3. Furthermore, recent studies demonstrated that Smad3 mediates renal fibrosis by down-regulating miR-29 and miR-200 but up-regulating miR-21 and miR-192. Thus, overexpression of miR-29 and miR-200 or down-regulation of miR-21 and miR-192 is capable of attenuating Smad3-mediated renal fibrosis in various mouse models of chronic kidney diseases (CKD). Taken together, TGF-β/Smad signaling plays an important role in renal fibrosis. Targeting TGF-β/Smad3 signaling may represent a specific and effective therapy for CKD associated with renal fibrosis. INTRODUCTION The TGF-β superfamily consists of highly pleiotropic molecules including activins, inhibins, BMPs (Bone morphogenic proteins), GDFs (Growth differentiation factors) and GDNFs (Glial-derived neurotrophic factors), and exerts multiple biological functions in renal inflammation, fibrosis, cell apoptosis, and proliferation (Massague and Wotton, 2000). Among them, TGF-β is known as a key pro-fibrotic mediator in fibrotic diseases. Three isoforms of TGF-β have been identified in mammals, termed TGF-β1, 2, and 3, of which TGF-β1 is the most abundant isoform and can be produced by all types of renal resident cells. After synthesis, TGF-β1 is released in association with LAP (latency-associated peptide) as a latent form of TGF-β1 which binds to LTBP (Latent TGF-β-binding protein) in the target tissues. When exposed to multiple types of stimuli, including ROS (Reactive oxygen species), plasmin and acid (Lyons et al., 1990; Munger et al., 1999; Meng et al., 2013), TGF-β1 can be released from the LAP and LTBP and becomes active. The active TGF-β1 then binds to TβRII (Type II TGF-β receptor), a constitutively active kinase, which recruits TβRI (Type I TGF-β receptor) and phosphorylates the downstream receptor-associated Smads (R-Smads) i.e., Smad2 and Smad3 (Wrana et al., 1994). Then the phosphorylated Smad2 and Smad3 form an oligomeric complex with a common Smad, Smad4, and translocates into the nucleus to regulate the transcription of target genes in collaboration with various co-activators and co-repressors. It is interesting that an inhibitory Smad, Smad7, can be induced in a Smad3-dependent manner. Smad7 consequently competes with the R-Smads for binding to the activated receptors, in order to exert its negative effect on TGF-β/Smad signaling (Shi and Massague, 2003). Additionally, TGF-β1 is able to function through the Smad-independent pathways, including p38, ERK (Extracellular-signal-regulated kinase), MAPK, Rho-GTPases, Rac, Cdc42, ILK (Integrin linked kinase) (Attisano and Wrana, 2002; Derynck and Zhang, 2003; Li et al., 2009; Loeffler and Wolf, 2014). In this review, we focus on the pathological roles of TGF-β/Smad signaling in renal fibrosis. ROLE OF TGF-Β1 IN RENAL FIBROSIS Renal fibrosis, characterized by excessive deposition of ECM (Extracellular matrix), is recognized as a common pathological feature of CKD (Chronic kidney diseases) which leads to the development of ESRD (End-stage renal disease), accompanied by a progression of renal malfunctions (Eddy and Neilson, 2006). Although effective therapy for renal fibrosis is still lacking, a number of studies demonstrated that TGF-β is the key mediator in CKD associated with progressive renal fibrosis. It is well documented that TGF-β1 has multiple biological properties including cell proliferation, differentiation, apoptosis, autophagy, production of ECM, etc. (Meng et al., 2013). Considerable evidence revealed that TGF-β is substantially upregulated in the injured kidney on both patients and animal disease models (Yamamoto et al., 1996; Bottinger and Bitzer, 2002). It is also showed that the urinary levels of TGF-β are significantly increased in patients with various renal diseases, which is positively correlated with the degree of renal fibrosis (Murakami et al., 1997). Moreover, the importance of TGF-β1 in renal fibrosis is further supported by the findings that overexpression of active TGF-β1 in rodent liver is capable of inducing the fibrotic response in kidney; whereas blocking TGF-β with neutralizing antibody, antisense oligonucleotides, inhibitors, or genetic deletion of receptors can attenuate kidney fibrosis in vivo and in vitro (Sanderson et al., 1995; Kopp et al., 1996; Border and Noble, 1998; Moon et al., 2006; Petersen et al., 2008; Meng et al., 2012a). In contrast to the active form of TGF-β1, the latent form of TGF-β1 can protect the kidney against fibrosis and inflammation by upregulating Smad7 that is observed in the latent TGF-β transgenic mice received with UUO-induced nephropathy or anti-GBM-induced glomerulonephritis (Huang et al., 2008a,b). Taken together, TGF-β exerts profibrotic effects on the kidney through several possible mechanisms: (1) TGF-β1 directly induces the production of ECM, including collagen I and fibronectin, through the Smad3-dependent or -independent mechanisms (Samarakoon et al., 2012); (2) TGF-β1 suppresses the degradation of ECM by inhibiting MMPs (Matrix metalloproteinases) but inducing TIMPs (Tissue inhibitor of metalloproteinase) and the natural inhibitor of MMPs; (3) TGF-β1 is believed to play critical roles in the transdifferentiation toward myofibroblast of several types of cells, including epithelial cells, endothelial cells, and pericytes, although the origin of myofibroblast is still undefined (Meng et al., 2013; Wu et al., 2013); (4) TGF-β1 acts directly on different types of renal resident cells, for example: it can promote the proliferation of mesangial cells in order to increase matrix production, or induce the elimination of tubular epithelial cells and podocytes which may lead to a deterioration of renal injury and incur more severe renal fibrosis (Bottinger and Bitzer, 2002; Lopez-Hernandez and Lopez-Novoa, 2012) (Figure 1). [Figure: Role of TGF-β/Smad signaling in kidney disease. TGF-β1 signals through the downstream mediators to exert its biological activities on different cell types of kidney cells during renal inflammation and fibrosis.] ROLE OF SMADS IN RENAL FIBROSIS Smad2 and Smad3 It is consistently demonstrated that Smad2 and Smad3 are extensively activated in the fibrotic kidney in patients and animal models with CKD (Meng et al., 2013). Although Smad2 and Smad3 share more than 90% similarity in their amino acid sequences, their functional roles in renal fibrosis are distinct. It is well documented that Smad3 is pathogenic since knockout of Smad3 gene inhibits fibrosis in obstructive nephropathy (Sato et al., 2003), diabetic nephropathy (Fujimoto et al., 2003), hypertensive nephropathy (Liu et al., 2012), and drug-toxicity-related nephropathy (Zhou et al., 2010). Of note, Smad3 promotes renal fibrosis by directly binding to the promoter region of collagens to trigger their production (Vindevoghel et al., 1998; Chen et al., 1999), and inhibiting the ECM degradation via induction of TIMP-1 while reducing MMP-1 activities in fibroblasts (Yuan and Varga, 2001). In contrast to Smad3, Smad2 is unable to directly bind to the genomic DNA (Dennler et al., 1998). Previous study suggested that roles of Smad2 and Smad3 might